Prices are falling for the popular obesity treatments Wegovy and Zepbound, but steady access to the drugs remains challenging ...

Prices are falling for the popular obesity treatments Wegovy and Zepbound, but steady access to the drugs remains challenging. The ...

NVO shares fall 19.9% year to date amid weak CagriSema data, CEO exit and rising pressure from rivals in obesity care.

There’s a perception that Ozempic, Wegovy and Zepbound are all you need to live a healthier life. But diet and exercise still ...

According to a new feature by the Washington Post, approximately 16 million American adults are on GLP-1 drugs such as ...

Folks on GLP-1 drugs can expect to maintain their weight loss if they have a disruption in access, as long as they’ve also ...

Hengrui has reported topline data from the 301 study of their dual GLP-1 and GIP agonist HRS9531, administered as a ...

Wegovy, a weight loss drug, is gaining popularity for its effectiveness, but experts emphasize that it's most successful when ...

Research indicates GLP-1 receptor agonists, like Ozempic, may elevate testosterone levels in men while promoting weight loss.

Connecticut passed a new law last week in an effort to lower its spending on weight-loss drugs for its state insurance ...

The new arrangement could cut patients' copays to $25 per month, or less, for Wegovy, Zepbound, Ozempic and Rybelsus ...

Pharmacy benefit manager CVS Caremark drops Zepbound coverage, estimating 10-15% savings while Eli Lilly offers self-pay ...